Seroprevalence of the SARS-CoV-2 antibody in healthcare workers: a multicentre cross-sectional study in 10 Colombian cities

Occup Environ Med. 2022 Jun;79(6):388-395. doi: 10.1136/oemed-2021-107487. Epub 2021 Nov 5.

Abstract

Background: Healthcare workers are at increased risk of infection due to occupational exposure to SARS-CoV-2-infected patients. The objective of this study was to determine the seroprevalence of SARS-CoV-2 in healthcare workers in Colombia.

Methods: This study is a cross-sectional study focused on estimating the seroprevalence of SARS-CoV-2 antibodies in healthcare workers from 65 hospitals in 10 cities in Colombia during the second semester of 2020. The seroprevalence was determined using an automated immunoassay (Abbott SARS-CoV-2 CLIA IgG). The study included a survey to establish the sociodemographic variables and the risk of infection. A multivariate model was used to evaluate the association between the results of seroprevalence and risk factors.

Results: The global seroprevalence of antibodies against SARS-CoV-2 was 35% (95% Bayesian CI 33% to 37%). All the personnel reported the use of protective equipment. General services personnel and nurses presented the highest ratios of seroprevalence among the healthcare workers. Low socioeconomic strata have shown a strong association with seropositivity.

Conclusion: This study estimates the prevalence of SARS-CoV-2 infection among healthcare workers. Even though all the personnel reported the use of protective equipment, the seroprevalence in the general services personnel and nurses was high. Also, a significant difference by cities was observed.

Keywords: COVID-19; cross-sectional studies; health personnel; occupational health; public health.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • Bayes Theorem
  • COVID-19* / epidemiology
  • Cities / epidemiology
  • Colombia / epidemiology
  • Cross-Sectional Studies
  • Health Personnel
  • Humans
  • Immunoglobulin G
  • SARS-CoV-2*
  • Seroepidemiologic Studies

Substances

  • Antibodies, Viral
  • Immunoglobulin G